Development and pharmacological evaluation of a PEG based nanoparticulate camptothecin analog for oral administration

Current Drug Delivery

Volumn 8, Issue 6, 2011, Pages 661-666

  Nekkanti, Vijaykumar ^a   Venkateswarlu, Vabalaboina ^a   Ansari, Khalid Akhter ^a   Pillai, Raviraj ^a  

^a DR REDDY'S LABORATORIES LTD   (India)

Author keywords

Camptothecin analog; High pressure homogenization; Low bioavailability; Nanoparticles

Indexed keywords

CAMPTOTHECIN DERIVATIVE; IRINOTECAN; MACROGOL; NANOPARTICLE;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL STRAIN NCI H460; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SOLUBILITY; MALE; NONHUMAN; NUDE MOUSE; PARTICLE SIZE; PRIORITY JOURNAL; RAT; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL LINE, TUMOR; DRUG CARRIERS; DRUG STABILITY; FEMALE; HUMANS; LECITHINS; MALE; MICE; MICE, NUDE; NANOPARTICLES; NEOPLASMS; PARTICLE SIZE; POLYETHYLENE GLYCOLS; RATS; RATS, WISTAR; SOLUBILITY; TOPOISOMERASE I INHIBITORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80054064908     PISSN: 15672018     EISSN: 18755704     Source Type: Journal    
DOI: 10.2174/156720111797635469     Document Type: Article

References (22)

1. Lipinski, C. Poor aqueous solubility-an industry wide problem in drug discovery, Am. Pharm. Rev., 2002, 5, 82-85.
2. Hecq, J.; Deleers, M.; Fanara, D.; Vranckx, Amighi, K. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine, Int. J. Pharm., 2005, 299, 167-177.
3. Aungst, B.J. Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation or presystemic metabolism, J. Pharm. Sci., 1993, 82, 979-987.
4. Nekkanti, V.; Karatgi, P.; Prabhu, R.; Pillai, R. Solid self-micro emulsifying formulation for candesartan cilexetil. AAPS Pharm. Sci. Tech., 2009, DOI 10.1208/s12249-009-9347-6.
5. Möschwitzer, J.; Achleitner, G.; Pomper, H.; Müller, R.H. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology, Eur. J. Pharm. Biopharm., 2004, 58, 615-619.
6. Liversidge, G.G.; Conzentino, P. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxenin rats, Int. J. Pharm., 1995, 125, 309-313.
7. Peters, K.; Leitzke, S.; Diederichs, J.E.; Borner, K.; Hahn, H.; Müller, R.H.; Ehlers, S. Preparation of clofazamine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in Mycobacterium avium infection. J. Antimicrob. Chem., 2000, 45, 77-83.
8. Trotta, M.; Gallarete, M.; Pattarino, F.; Morel, S. Emulsions containing partially water-miscible solvents for the preparation of drug nanosuspensions, J. Control. Release., 2001, 76, 119-128.
9. Debuigne, F.; Cuisenaire, J.; Jeunieau, L.; Masereel, B.; Nagy, J.B. Synthesis of nimesulid nanoparticles in the microemulsion epikuron/isopropyl myristate/water/n-butanol (or isopropanol), J. Colloid. Interface Sci., 2001, 243, 90-101.
10. Hertzberg, R.P.; Caranfa, M.J.; Hecht, S.M. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry, 1989, 28, 4629-4638.
11. Takimoto, C.H.; Wright, J.; Arbuck, S.G. Clinical applications of the camptothecins, Biochim. Biophys. Acta., 1998, 1400, 107-119.
12. Potmesil, M.; Pinedo, H.M. Camptothecins: New Anticancer Agents. CRC Press, Boca Raton., 1995.
13. Dancey, J.; Eisenhauer, E.A. Current perspective on Camptothecins in cancer treatment. Br. J. Cancer., 1996, 74, 327-338.
14. Pharmaceutical compositions of [5(S)-(2'-hydroxyethoxy)-20(S)-Camptothecin] PCT W02008/148080A2, December 04, 2009.
15. Muller, C.; Jacobs, R.H.; Kayser, O. Disso Cubes - a novel formulation for poorly soluble and poorly bioavailable drugs in: Rathbone, M.J. Hadgraft, Roberts Eds. J. M.S., Modified-Release Drug Delivery Systems, Marcel Dekker, New York, 2003, pp. 135-149.
16. Herold, D.A.; Keil, K.; Bruns, D.E. Oxidation of polyethylene glycols by alcohol dehydrogenase, Biochem. Pharmacol., 1989, 38, 73-76.
17. Hatefi, A.; Amsden, B. Camptothecin delivery methods. Pharm. Res., 2002, 19, 1389-1399.
18. Scenderova, A.; Burke, T.; Schwendeman, S. Stabilization of 10-hydroxycamptothecin in poly (lactide-co-glycolide) microsphere delivery vehicles. Pharm. Res., 1997, 14, 1406.
19. Cortesi, R.; Esposito, E.; Maietti, A.; Menegatti, E.; Nastruzzi, C. Formulation study for the antitumor drug camptothecin: liposomes, micellar solutions and a microemulsion. Int. J. Pharm., 1997, 159, 95-103.
20. Kunii, R.; Onishi, H.; Machida, Y. Preparation and antitumor characteristics of PLA/(PEG-PPG-PEG) nanoparticles loaded with camptothecins, Eur. J. Pharm. Biopharm., 2007, 67, 9-17.
21. Davis, M.E. Design and development of IT-101, a cyclodextrin containing polymer conjugate of camptothecins. Adv. Drug Del. Rev., 2009, 61, 1189-1192.
22. Muller, R.H.; Jacobs, C.; Kayser, O. Nanosuspensions as particulate drug formulations in therapy rationale for development and what we can expect for the future. Adv. Drug. Del. Rev., 2001, 47, 3-19.